All product and company names are trademarks^™ or registered^® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them.

*Breakthrough therapy designation granted for cholangiocarcinoma.

Reference: 1 Markets Insider. Elevar Therapeutics Receives Orphan Drug Designation from FDA for Rivoceranib for the Treatment of Hepatocellular Carcinoma (HCC). Published November 11, 2021. Accessed June 1, 2023. https://markets.businessinsider.com/news/stocks/elevar-therapeutics-receives-orphan-drug-designation-from-fda-for-rivoceranib-for-the-treatment-of-hepatocellular-carcinoma-hcc-1030965744